🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis

Recruitingn/aAges 18 Years - anyAllVirginia Commonwealth University
NCT05720663 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions. Decompensation occurs when the liver becomes unable to perform all of its functions adequately. Variceal hemorrhage (bleeding from abnormal vessels in the liver called varices), Ascites (abnormal build-up of fluid in the abdomen), and Encephalopathy (brain confusion as a result of the liver not being able to get rid of toxic substances) are three symptoms of liver decompensation. The purpose of this research study is to investigate better ways to routinely monitor the condition of patients with NASH with compensated cirrhosis and to better pinpoint the development of decompensation in the livers of these patients.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Adult patients with presence of NAFLD associated cirrhosis. * Cirrhosis: biopsy confirmed or Agile F (F4) score \> 0.45 * NAFLD as an etiology of liver disease will be determined based on presence of any of the following: * Biopsy showing \>5% steatosis or * CAP \> 280 dB/m or MR-PDFF\>5% * If CAP \< 280 dB/m or MR-PDFF \<5%, then must have type 2 diabetes and or 2 or more features of metabolic syndrome for 5 years (cryptogenic cirrhosis) Exclusion Criteria: * Refusal to consent * Alcohol use \> 14/21 gm/week cutoff * Other causes of chronic liver disease * MELD \> 12 * Hepatic and extrahepatic cancers expected to limit life expectancy \< 2 yrs * prior hepatic resections, TIPS, splenic embolization * prior decompensation events * inability to fit into MRI (failed hula-hoop test) * general contraindication for MRI contrast (GFR \< 30 ml/min) * contraindications for MRI * pregnancy * acute kidney injury * reduced kidney function (GFR \<30ml/min)
💊

What it tests

  • Standard of care
📍

Where

2 sites
Mayo Clinic in Rochester
Rochester, United States
Virginia Commonwealth University
Richmond, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy